10-K: ThermoGenesis Holdings, Inc. Files 10-K Report, Details Financials and Strategic Initiatives

ThermoGenesis Holdings, Inc. released its annual 10-K report, outlining its financial performance, strategic initiatives, and risk factors for the fiscal year ended December 31, 2023.

Summary

• ThermoGenesis Holdings, Inc. reported a net revenue of $9.445 million for 2023, a decrease of 10% compared to $10.483 million in 2022.
• The decrease in revenue was primarily due to a reduction in AXP disposable sales, which was partially offset by increased AXP device sales and BioArchive revenue.
• The company's gross profit decreased to $1.931 million, or 20% of net revenues, compared to $2.710 million, or 26%, in the previous year, mainly due to additional inventory reserves.
• Operating expenses totaled $10.541 million, including selling, general, and administrative expenses of $7.221 million and research and development expenses of $1.284 million.
• The company incurred impairment charges of $2.036 million due to a significant decline in its stock price and the non-renewal of a distribution agreement.
• Interest expense increased to $10.032 million, driven by additional amortization expense related to the conversion price of notes.
• The company had a net loss of $18.919 million for 2023, compared to a net loss of $11.812 million in 2022.
• As of December 31, 2023, the company had cash and cash equivalents of $2 million and a working capital deficit of $6.582 million.
• The company has a revolving credit agreement with Boyalife Group, Inc., with an outstanding balance of $7.278 million as of December 31, 2023.
• The company's independent auditors included an explanatory paragraph in their report indicating substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with declining revenues, reduced profitability, significant losses, and a going concern warning. While there are some positive developments, the overall tone is negative from an investment perspective.

Positives

• AXP device sales increased in 2023, indicating new customer adoption of the technology.
• BioArchive revenue increased in 2023, primarily due to higher service revenue.
• The company completed its new state-of-the-art CDMO facility in October 2023, expanding its service offerings.
• The company has over 30 issued patents globally relating to its medical devices.

Negatives

• The company experienced a 10% decrease in net revenues year-over-year.
• Gross profit margin decreased from 26% to 20% due to increased inventory reserves.
• The company incurred significant impairment charges of $2.036 million.
• Interest expense increased substantially to $10.032 million.
• The company reported a net loss of $18.919 million for 2023.
• The company has a significant working capital deficiency and needs to raise additional capital.
• The company's independent auditors expressed substantial doubt about its ability to continue as a going concern.
• The company identified a material weakness in internal controls over financial reporting.
• The company's distribution agreement with Corning was not extended, impacting future revenue projections.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional capital.
• The company's largest stockholder has significant influence, which could limit other investors' ability to influence key transactions.
• The company relies on a few significant customers, and the loss of one could significantly impact revenue.
• The company has limited sales, marketing, and distribution capabilities, which may hinder growth.
• The company's inability to protect its intellectual property could adversely impact its competitive position.
• The company's products may be subject to recalls, which could harm its reputation and divert resources.
• The company is dependent on third-party suppliers and manufacturers, which could lead to production delays.
• The company's new CDMO business is subject to the risks associated with entering a new business line.
• The company's stock may be delisted from Nasdaq if it does not meet minimum bid price requirements.
• The company is subject to the Foreign Corrupt Practices Act, and violations could have a material adverse effect.

Future Outlook

The company expects its production capacity in 2024 to be sufficient to meet demand. The company will need to raise additional capital to grow its business, fund operating expenses, and make interest payments. The company is exploring additional funding through debt borrowings, sales of debt or equity securities, or strategic partnerships.

Management Comments

• Management believes that its customers and distributors are sound and creditworthy.
• Management believes that any liability that may ultimately result from the resolution of disputes will not have a material adverse effect on the company's consolidated financial position, operating results, or cash flows.

Industry Context

The company operates in the cell-banking, cell-processing, and cell-based therapeutics industry, which is heavily regulated and competitive. The company's expansion into CDMO services reflects a broader trend in the industry towards outsourcing manufacturing for cell and gene therapies. The company faces competition from larger, well-established manufacturers and academic institutions.

Comparison to Industry Standards

• ThermoGenesis's revenue decline contrasts with the growth seen in some areas of the cell and gene therapy sector, where companies with approved therapies or strong clinical pipelines have experienced significant investment and revenue growth.
• The company's gross profit margin of 20% is lower than the industry average for medical device companies, which typically range from 40% to 60%.
• The company's high interest expense and net losses are concerning compared to more established companies in the sector, such as Lonza or Catalent, which have more diversified revenue streams and stronger balance sheets.
• The company's reliance on a single large customer and a limited number of suppliers is a risk factor that is not typical of larger, more diversified companies in the industry.
• The company's CDMO expansion is similar to moves by other companies in the sector, such as WuXi AppTec and Samsung Biologics, but ThermoGenesis is at an earlier stage of development and faces significant competition.

Management Changes

Corporate Governance

Legal Proceedings

• The company may have disagreements or disputes with distributors, vendors, or employees in the normal course of operations.
• Management does not believe that any pending legal proceedings are material.

Related Party Transactions

• The company has a revolving credit agreement with Boyalife Group, Inc., which is owned and controlled by the company's CEO.
• The company has a lease agreement with Z3 Investment LLC, an affiliate of the company's Chairman and CEO.
• The company has a First Amended and Restated Nomination and Voting Agreement with Boyalife Asset Holding II, Inc., its largest stockholder.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial condition and the potential for delisting.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may be concerned about the company's ability to continue operations and provide ongoing support.
• Suppliers may face increased credit risk due to the company's financial challenges.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to work to remediate the material weaknesses identified in its internal controls.
• The company will seek additional funding through debt borrowings, sales of debt or equity securities, or strategic partnerships.
• The company will focus on growing its CDMO business and leveraging its automated cell processing technologies.

Key Dates

Keywords

ThermoGenesis, cell therapy, CDMO, medical devices, bio-banking, AXP, BioArchive, financial results, 10-K, internal controls, revenue, net loss, going concern, stock split, intellectual property, regulatory compliance